{
    "clinical_study": {
        "@rank": "8165", 
        "arm_group": [
            {
                "arm_group_label": "Botox\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "Botox\u00ae"
            }, 
            {
                "arm_group_label": "miraDry\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "miraDry\u00ae"
            }, 
            {
                "arm_group_label": "Nd: YAG laser", 
                "arm_group_type": "Experimental", 
                "description": "Nd: YAG laser  1440nm"
            }
        ], 
        "brief_summary": {
            "textblock": "The Purpose of the study is to evaluate the 1440nm Laser Assisted Selective Photothermolysis\n      vs. Botulinum Toxin or miraDry\u00ae Microwave Thermolysis For Treatment of Axillary\n      Hyperhidrosis."
        }, 
        "brief_title": "Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry\u00ae Microwave For Treatment of Axillary Hyperhidrosis", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperhidrosis", 
        "condition_browse": {
            "mesh_term": "Hyperhidrosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A healthy non-smoking male or female between 18-70 years of age\n\n          -  Understand/accept obligation not to receive any other procedures in anatomical areas\n             exhibiting axillary hyperhidrosis through 3 months prior to treatment\n\n          -  Understand and accept the obligation and is logistically able to present for all\n             scheduled follow-up visits\n\n          -  Clinically diagnosed for primary hyperhidrosis of the axilla.\n\n          -  A self-assessed HDSS score of three (3) or four (4) a. Gravimetric >50mg/5min in each\n             axilla\n\n        Exclusion Criteria:\n\n          -  Clinical diagnosis of secondary hyperhidrosis\n\n          -  Uncontrolled systemic disease or infection\n\n          -  Concurrent use of any hyperhidrosis treatments other than OTC antiperspirants or\n             deodorants\n\n          -  Receipt of Botox\u00ae or Dysport\u00ae within the past six months\n\n          -  Patients who refuse to stop using OTC antiperspirants 24 hours prior to the day of\n             surgery and each of the follow-up visits at 3 months and 6 months that Minors starch\n             iodine tests may be performed.\n\n          -  Patients using or having used within 7 days of baseline visit: cholinomimetic agents,\n             anticholinergic agents, prescription antiperspirants, any herbal medicine treatments\n             or any other treatments for hyperhidrosis except OTC antiperspirant or planning to\n             use such agents during the course of the study.\n\n          -  Any previous liposuction/liposculpture or any type of surgery for hyperhidrosis; OR\n             any other types of treatments for hyperhidrosis in the area to be treated in the past\n             6 months\n\n          -  Has any other medical condition, that, in the investigator's opinion would interfere\n             with the subject's participation in the study\n\n          -  Is susceptible to light induced seizures or history of seizures\n\n          -  Has a history of keloid formation\n\n          -  Significant cardiovascular disease\n\n          -  Bleeding disorders\n\n          -  Anti-platelet and anticoagulant medication\n\n          -  Sensitivity to lidocaine or epinephrine\n\n          -  Pregnancy or planned pregnancy\n\n          -  Existing neuromuscular disorders (myasthenia gravis, Eaton-Lambert Syndrome,\n             amyotrophic lateral sclerosis)\n\n          -  Electronic implants\n\n          -  Subjects requiring supplemental oxygen\n\n          -  Has therapies or medications which may interfere with the treatment (including\n             medications causing photosensitivity\n\n          -  Allergic to Keflex"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811004", 
            "org_study_id": "CYN12-GS-HH01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "miraDry\u00ae", 
                    "Nd: YAG laser"
                ], 
                "description": "miraDry", 
                "intervention_name": "miraDry", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Botox\u00ae", 
                    "miraDry\u00ae", 
                    "Nd: YAG laser"
                ], 
                "description": "Nd:YAG 1440 nm Laser", 
                "intervention_name": "Nd:YAG Laser", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Botox\u00ae", 
                    "Nd: YAG laser"
                ], 
                "description": "Botox\u00ae", 
                "intervention_name": "Botox\u00ae", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pasadena", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91105"
                }, 
                "name": "Sasaki Advanced Aesthetic Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Comparison of Amount of Sweat Produced", 
            "safety_issue": "No", 
            "time_frame": "up to 12 months post treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Histological examination of tissue samples pre-treatment and 9 months post treatment to assess safety and tolerability", 
                "measure": "Subject biopsy sampling", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 9 months post treatment"
            }, 
            {
                "measure": "Satisfaction Questionnaires", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months post treatment"
            }
        ], 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}